MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Начало・Списък с акции・Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

Затворен

СекторЗдравеопазване

3.55 -1.93

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.54

Максимум

3.65

Ключови измерители
By Trading Economics
Приходи	5M -79M
Продажби	15M 74M
EPS	-0.26
Марж на печалбата	-106.602
Служители	838
EBITDA	14M -75M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+403.32% upside

Дивиденти
By Dow Jones
Следващи печалби	8.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-682M 1B
Предишно отваряне	5.48
Предишно затваряне	3.55

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

3.18 / 3.64 Подкрепа & съпротива

Iovance Biotherapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.04.2025 г., 23:27 ч. UTC

Топ новини

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- 2nd Update

28.04.2025 г., 23:07 ч. UTC

Топ новини

Woodside Energy Approves $17.5 Billion Louisiana LNG Development -- Update

28.04.2025 г., 23:03 ч. UTC

Печалби

Waste Management 1Q Profit Falls, Revenue Misses Estimates

28.04.2025 г., 23:47 ч. UTC

Пазарно говорене

Gold Edges Lower as Traders Assess Mixed Signals From Treasury Secretary Bessent -- Market Talk

28.04.2025 г., 23:17 ч. UTC

Печалби

Jiangxi Copper 1Q Rev CNY111.61B Vs. CNY122.52B >0358.HK

28.04.2025 г., 23:17 ч. UTC

Печалби

Jiangxi Copper 1Q Net CNY1.95B Vs. Net CNY1.71B >0358.HK

28.04.2025 г., 23:13 ч. UTC

Печалби

China Merchants Securities: Higher Interest Income, Fee Income Also Aided 1Q Results>600999.SH

28.04.2025 г., 23:13 ч. UTC

Печалби

China Merchants Securities 1Q Rev CNY4.71B Vs. CNY4.30B >600999.SH

28.04.2025 г., 23:13 ч. UTC

Печалби

China Merchants Securities: Gains From Investments in Financial Instruments Supported Results >600999.SH

28.04.2025 г., 23:13 ч. UTC

Печалби

China Merchants Securities 1Q Net CNY2.31B Vs. Net CNY2.16B >600999.SH

28.04.2025 г., 23:08 ч. UTC

Печалби

China Longyuan Power: 1Q Power Generation Declined 4.42% on Year>0916.HK

28.04.2025 г., 23:08 ч. UTC

Печалби

China Longyuan Power 1H Rev CNY8.14B Vs. CNY8.07B >0916.HK

28.04.2025 г., 23:08 ч. UTC

Печалби

China Longyuan Power 1H Net CNY1.98B Vs. Net CNY2.53B >0916.HK

28.04.2025 г., 23:04 ч. UTC

Печалби

Huaneng Power: 1Q Net Was Mainly Driven By Decline in Domestic Fuel Costs >0902.HK

28.04.2025 г., 23:04 ч. UTC

Печалби

Huaneng Power: Decrease in Electricity Tariffs Weighed on Rev >0902.HK

28.04.2025 г., 23:04 ч. UTC

Печалби

Huaneng Power 1Q Rev CNY60.33B ; Down 7.7% on Year>0902.HK

28.04.2025 г., 23:04 ч. UTC

Печалби

Huaneng Power 1Q Net CNY4.97B; up 8.2% on Year >0902.HK

28.04.2025 г., 23:00 ч. UTC

Печалби

Jiangsu Expressway 1Q Rev CNY4.78B Vs. CNY3.47B >0177.HK

28.04.2025 г., 23:00 ч. UTC

Печалби

Jiangsu Expressway: 1Q Rev Rose Due to Increase in Road Construction Projects >0177.HK

28.04.2025 г., 23:00 ч. UTC

Печалби

Jiangsu Expressway: Decline in Investment Income, Fall in Revenue Post Asset Disposal Weighed on 1Q Net >0177.HK

28.04.2025 г., 23:00 ч. UTC

Печалби

Jiangsu Expressway 1Q Net CNY1.21B Vs. Net CNY1.25B >0177.HK

28.04.2025 г., 22:57 ч. UTC

Топ новини

Trump Signs Order Requiring Nationwide List of Sanctuary Cities and States -- 8th Update

28.04.2025 г., 22:55 ч. UTC

Печалби

Tsingtao Brewery: Higher Sales Volumes of Beer Supported Results >0168.HK

28.04.2025 г., 22:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Net CNY1.71B Vs. Net CNY1.60B >0168.HK

28.04.2025 г., 22:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Rev CNY10.45B Vs. CNY10.15B >0168.HK

28.04.2025 г., 22:52 ч. UTC

Печалби

S.F. Holding: Results Supported by Higher Contributions From Logistics Business >002352.SZ

28.04.2025 г., 22:52 ч. UTC

Печалби

S.F. Holding 1Q Net CNY2.23B Vs. Net CNY1.91B >002352.SZ

28.04.2025 г., 22:52 ч. UTC

Печалби

S.F. Holding: Cost Controls Also aided 1Q Results >002352.SZ

28.04.2025 г., 22:52 ч. UTC

Печалби

S.F. Holding 1Q Rev CNY69.85B Vs. CNY65.34B >002352.SZ

28.04.2025 г., 22:46 ч. UTC

Печалби

Shandong Gold Mining: Increase in Selling Price of Gold Supported Results>600547.SH

Сравнение с други в отрасъла

Ценова промяна

Iovance Biotherapeutics Inc Прогноза

Ценова цел

By TipRanks

403.32% нагоре

12-месечна прогноза

Среден 18.17 USD 403.32%

Висок 32 USD

Нисък 5 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Iovance Biotherapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Iovance Biotherapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.18 / 3.64Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.